These authors contributed equally to this study.
Phosphoproteome profiling of substantia nigra and cortex regions of Alzheimer’s disease patients
Article first published online: 24 APR 2012
© 2012 The Authors. Journal of Neurochemistry © 2012 International Society for Neurochemistry
Journal of Neurochemistry
Volume 121, Issue 6, pages 954–963, June 2012
How to Cite
Zahid, S., Oellerich, M., Asif, A. R. and Ahmed, N. (2012), Phosphoproteome profiling of substantia nigra and cortex regions of Alzheimer’s disease patients. Journal of Neurochemistry, 121: 954–963. doi: 10.1111/j.1471-4159.2012.07737.x
- Issue published online: 8 JUN 2012
- Article first published online: 24 APR 2012
- Accepted manuscript online: 21 MAR 2012 10:06AM EST
- Received August 29, 2011; revised manuscript received February 2, 2012; accepted March 9, 2012.
- Alzheimer’s disease;
- substantia nigra
J. Neurochem. (2012) 121, 954–963.
Alzheimer’s disease (AD) is the most common form of dementia and cognitive impairment usually characterized by widespread neurodegeneration throughout the association cortex, limbic system and hippocampus. Aberrant protein phosphorylation is a defining pathological hallmark of AD and implicated in the dysregulation of major cellular processes through highly dynamic and complex signaling pathways. Here in, we demonstrate 81 proteins, of 600 spots selected, unambiguously identified as phosphorylated, providing a partial phosphoproteome profile of AD substantia nigra and cortex and respective control brain regions. More importantly, abnormal phosphorylation signal intensity of nine physiologically important proteins observed can profoundly affect cell metabolism, signal transduction, cytoskeleton integration, and synaptic function and accounts for biological and morphological alterations. Our studies employed two-dimensional gel electrophoresis for protein separation, Pro-Q® Diamond phosphoprotein staining and electrospray ionization quadrupole time of flight tandem MS for protein identification. NetPhosk 1.0 is used for the confirmation of protein modification status as well known/putative phosphoproteins. A further insight into the links among the identified phosphoproteins and functional roles STRING 8.3, KEGG and REACTOME pathway databases were applied. The present quantitative phosphoproteomic analysis can be supportive in establishing a broad database of potential protein targets of abnormal phosphorylation in AD brain.